Legend Biotech Corporation
LEGN
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatmā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$37.50
Price-0.56%
-$0.21
1Y
Price
Market Cap
$3.444b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-19.6%
EBITDA Margin-9.8%
Net Profit Margin-11.2%
Free Cash Flow MarginRevenue
$728.303m
+59.9%
1y CAGR+78.0%
3y CAGR+63.1%
5y CAGREarnings
-$218.149m
+45.0%
1y CAGR+4.4%
3y CAGR-3.5%
5y CAGREPS
-$2.38
+46.6%
1y CAGR+13.1%
3y CAGR+8.2%
5y CAGRBook Value
$1.018b
$1.616b
Assets$597.900m
Liabilities$362.810m
DebtDebt to Assets
22.5%
-1x
Debt to EBITDAFree Cash Flow
-$273.167m
+58.0%
1y CAGR-20.0%
3y CAGR-12.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company